Specialty medical injectable drug program, requirements and drug policy updates for September
New specialty medical injectable updates and requirements announced September 2024.
Review the following tables to determine changes to our specialty medical injectable drug programs.
SPECIALTY MEDICAL INJECTABLE DRUGS ADDED TO REVIEW AT LAUNCH
For UnitedHealthcare Commercial business
| Drug Name | Treatment Uses |
| PiaSky® (crovalimab-akkz) |
Used to treat adult and pediatric patients 13 years of age and older with paroxysmal nocturnal hemoglobinuria and a body weight of at least 40 kg. |
Yimmugo® |
Used to treat primary humoral immunodeficiency in patients 2 years of age and older. |
Note: Drugs added to Review at Launch may not yet be available in the marketplace.
SPECIALTY MEDICAL INJECTABLE DRUGS ADDED TO MEDICATION SOURCING FOR ALL OUTPATIENT HOSPITAL PROVIDERS ONLY
For UnitedHealthcare Commercial business
| Drug Name | Effective Date | Therapeutic Class | HCPCS Code(s) | Specialty Pharmacy |
| Beqvez™ (fidanacogene elaparvovec-dzkt) |
10/1/24 | Gene Therapy | J3490 J3590 C9399 |
Please contact UHC Provider Services at the number on the back of the member ID card for available options |
Review the UnitedHealthcare Commercial Plan Medication Sourcing List.
For questions, please contact your broker or UnitedHealthcare representative.
Share
